Share Twitter LinkedIn Facebook Email Noa Biran, MD, talks about her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at the 2018 Annual Meeting.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read